Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Collegium secures $339M through term loan agreement, public debt raise to finance Nucynta deal

Executive Summary

Collegium Pharmaceutical Inc. received a total of $339.4M in committed debt financing to support in part its concurrent $375M purchase of US rights to oral opioid analgesic Nucynta (tapentadol) from its 2017 partner Assertio Therapeutics Inc. It secured a $200M term loan facility from BioPharma Credit PLC. The four-year loan will bear interest at a rate based upon LIBOR, plus 7.5% per annum. The company also publicly sold $143.75M ($139.4M net), including the overallotment, in 2.625% convertible senior notes due 2026.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO
    • Nonconvertible Debt
    • Convertible Debt

Related Companies